erlotinib hydrochloride has been researched along with everolimus in 33 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (12.12) | 29.6817 |
| 2010's | 25 (75.76) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Jackman, D; Jänne, PA; Johnson, BE | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Collins, MH; Cripe, TP; Johansson, G; Kim, MO; Kozma, SC; Lane, HA; Mahller, YY; Nobukuni, T; Perentesis, J; Ratner, N; Thomas, G | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Mehta, SP | 1 |
| Abbruzzese, JL; Davis, D; Fogelman, D; Javle, MM; Reddy, SA; Shroff, RT; Varadhachary, GA; Wolff, RA; Xiong, H; Zhang, Y | 1 |
| Ikemura, S; Ishizaka, A; Kawada, I; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Bago-Horvath, Z; Berger, W; Cejka, D; Filipits, M; Haitel, A; Hayden, H; Herberger, B; Schmid, K; Sieghart, W; Werzowa, J | 1 |
| Bendell, JC; Blobe, GC; Broadwater, G; Bullock, KE; Gockerman, JP; Howard, LA; Hurwitz, HI; Lager, JJ; Meadows, KL; Morse, MA; O'Neill, MM; Petros, WP; Truax, R; Uronis, HE; Younis, I; Zafar, SY | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Gemma, A; Saito, Y | 1 |
| Okamoto, T; Onda, S | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Botting, GM; Fong, JT; Jacobs, RJ; Moravec, DN; Nlend, M; Puri, N; Uppada, SB | 1 |
| Bennouna, J; Besse, B; Blais, N; Gogov, S; Jehl, V; Johnson, BE; Leighl, N; Miller, N; Papadimitrakopoulou, VA; Soria, JC; Traynor, AM | 1 |
| Benhadji, KA; Brail, LH; Bumgardner, W; Cohen, EE; Hollebecque, A; Houédé, N; Italiano, A; Massard, C; Miller, J; Soria, JC; Westwood, P | 1 |
| Takahashi, M | 1 |
| Bulusu, A; Dellinger, AE; Howard, LA; Hurwitz, HI; Jia, J; Kaplan, N; Li, H; Nixon, AB; Pang, H; Rushing, C; Weiss, ES | 1 |
| Blumenschein, GR; Canales, JR; Ginsberg, LE; Heymach, JV; Kies, MS; Lee, JJ; Lin, H; Lu, C; Massarelli, E; Papadimitrakopoulou, V; Tran, HT; Williams, MD | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Galani, V; Georgiou, I; Kitsou, C; Kosmas, IP; Lazaros, L; Markoula, S; Mynbaev, O; Peschos, D; Prapas, I; Prapas, N; Tournaye, H; Zikopoulos, A | 1 |
| Ali, SM; Blumenthal, DT; Bokstein, F; Dvir, A; Limon, D; Lior, T; Lokiec, A; Lossos, A; Ram, Z; Ross, JS; Soussan-Gutman, L; Tzuk-Shina, T; Yair, R; Yust-Katz, S | 1 |
| Bai, J; Chang, JY; Wang, P; Yuan, Z; Zhuang, H | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K | 1 |
| Aoki, M; Fujishita, T; Kajino-Sakamoto, R; Kojima, Y; Taketo, MM | 1 |
| Dekker, H; Labots, M; Meijer, GA; Pham, TV; Ruijter, R; Van der Hoeven, JJM; Van der Mijn, JC; Van der Vliet, HJ; Verheul, HMW | 1 |
| Aderhold, C; Birk, R; Huber, L; Kramer, B; Mueller, CE; Rotter, N; Schell, A | 1 |
| Aderhold, C; Birk, R; Huber, L; Jungbauer, F; Knuettel, M; Kramer, B; Lammert, A; Rotter, N; Scherl, C | 1 |
| Cole, BL; Leary, SES; Lockwood, CM; Starr, K | 1 |
| Dong, L; Jonas, JB; Li, H; Li, Y; Liu, Y; Nie, Y; Shao, L; Shi, X; Wei, W; Wu, H; Yang, Q; Yu, C; Zhang, C; Zhang, R; Zhou, W | 1 |
5 review(s) available for erlotinib hydrochloride and everolimus
| Article | Year |
|---|---|
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
7 trial(s) available for erlotinib hydrochloride and everolimus
| Article | Year |
|---|---|
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2010 |
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2011 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Treatment Outcome | 2014 |
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Everolimus; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Time Factors; Treatment Outcome; Vomiting | 2014 |
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Survival Rate | 2015 |
21 other study(ies) available for erlotinib hydrochloride and everolimus
| Article | Year |
|---|---|
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Nerve Sheath Neoplasms; Protein Kinases; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Up-Regulation | 2008 |
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Purines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Tumor Cells, Cultured | 2010 |
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenopus Proteins | 2010 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
[Lung injury].
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Lung Diseases; Quinazolines; Sirolimus | 2012 |
[Pancreatic carcinoma].
Topics: Erlotinib Hydrochloride; Everolimus; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2012 |
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
[Erlotinib, sunitinib, and everolimus].
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Everolimus; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2015 |
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.
Topics: Adult; Aged; Antibodies, Monoclonal; Bevacizumab; Biopsy, Needle; Clinical Trials as Topic; Disease-Free Survival; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Granulation Tissue; Humans; Male; Middle Aged; Panitumumab; Skin; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wound Healing | 2015 |
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Topics: AMP-Activated Protein Kinases; Animals; Capillary Permeability; Chorionic Gonadotropin; Erlotinib Hydrochloride; Everolimus; Female; Follicle Stimulating Hormone; Hormones; Infliximab; Metformin; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Reproductive Control Agents; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2015 |
Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Genomics; Glioma; Humans; Male; Middle Aged; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2016 |
MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Radiation-Sensitizing Agents; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Intestinal Neoplasms; MAP Kinase Signaling System; Mice, 129 Strain; Mice, Inbred C57BL; Morpholines; Neoplasm Invasiveness; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2017 |
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2018 |
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Papillomavirus Infections; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Squamous Cell Carcinoma of Head and Neck | 2020 |
FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus.
Topics: Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Fibroblast Growth Factors; Gefitinib; Human papillomavirus 16; Humans; Papillomaviridae; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases | 2020 |
The "SEED" Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors.
Topics: Brain Neoplasms; Child; Dasatinib; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Humans; Neoplasm Recurrence, Local; Patient Selection; Prospective Studies; Sorafenib; Young Adult | 2022 |
mTORC1 Signaling and Negative Lens-Induced Axial Elongation.
Topics: Animals; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Guinea Pigs; Intravitreal Injections; Male; Mammals; Myopia | 2023 |